Obesity medicines

What it is

Prescription medicines used for long-term weight management. Some mainly change weight. One also has evidence for major heart events in a specific high-risk group. Semaglutide 2.4 mg, tirzepatide, liraglutide, phentermine-topiramate, naltrexone-bupropion, and orlistat are named options in this conversation. Later-generation shots discussed in the news are not treated here as approved stand-ins.

What taking part usually involves

A clinician chooses a medicine based on your weight history, other conditions, heart history, access, and preferences. Follow-up usually includes weight checks and attention to class-specific side effects, especially stomach and bowel symptoms. Many people stop because of those effects. Canadian guidance treats these medicines as long-term therapy rather than a short course. This page does not tell you which medicine to start, and it does not give a compounding recipe.

In the large drug comparison used here, stopping because of side effects was highest with several medicines, including naltrexone-bupropion, liraglutide, phentermine-topiramate, and oral semaglutide, plus some later-generation shots still treated here as watches. Stomach and bowel events were most increased with naltrexone-bupropion, oral semaglutide, tirzepatide, and some of those later-generation shots.

What it is commonly confused with

“The medicine that loses the most weight must protect the heart the most.” “Heart-outcome evidence from one shot covers every GLP-1 and everyone with obesity.” “If guidelines disagree, medicines don't belong on the map.” “Compounded pens are the same as labeled medicines.” “Shots replace food, programs, or surgery.”

What the evidence shows

A network of 262 trials in 99,791 people compared obesity medicines with lifestyle change at one year. Tirzepatide produced the largest average weight loss among the better-supported findings, about 14.9%. Subcutaneous semaglutide was about 9.8%. Phentermine-topiramate was about 8.1%. Those are one-year weight rankings, not rankings of who prevents heart attacks.

Subcutaneous semaglutide is the medicine in that package uniquely tied to lower all-cause death and heart attack. That signal comes largely from heart-outcome trials in high-risk groups.

SELECT tested semaglutide 2.4 mg versus placebo in 17,604 adults aged 45 and older with preexisting heart disease, a BMI of 27 or higher, and no diabetes. Over a mean 39.8 months, major heart events occurred in 6.5% versus 8.0% (hazard ratio 0.80). That finding belongs to that medicine and that enrolled group. It does not travel to tirzepatide's larger weight effect. It does not cover people without established heart disease. Tirzepatide does not currently have that kind of completed obesity-without-diabetes heart-outcome trial.

Tirzepatide also reduced fat mass and lean mass in the comparison used here (about 25.7% fat and 8.3% lean mass). No medicine in that package improved quality of life beyond a small, pre-set threshold.

Older approved medicines stay named because people still use them and access is uneven. Later-generation neighbors reported in the same comparison at mixed or low certainty stay watches, not promoted treatments. Unregulated compounded products are a safety warning, not an option this page tries to optimize.

U.S., Canadian, and NICE guidance do not tell one first-line story. One is built around complications. One treats long-term pharmacotherapy with GRADE-style drug recommendations. One places medicines inside a service pathway. That disagreement is real. It does not erase the weight, harm, and selected heart-outcome evidence.

Who was studied, expectations, and limits

Population and context studied: adults with overweight or obesity in one-year medicine trials versus lifestyle change, plus SELECT's high-risk group with preexisting heart disease, BMI ≥27, and no diabetes. Guideline documents disagree about sequencing and about how long treatment continues.

That describes the research setting. It does not decide your personal regimen.

Realistic expectation: some medicines can produce substantial one-year weight loss, with stomach and bowel effects that lead many people to stop, and one medicine has heart-outcome evidence in a defined high-risk group. Limits: the biggest weight loss is not proven better heart protection; SELECT does not cover everyone with obesity; later-generation shots are not treated as approved equals; compounded pens are not labeled medicines; food, programs, exercise, and procedures stay on the map.